<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02581176</url>
  </required_header>
  <id_info>
    <org_study_id>CAP</org_study_id>
    <nct_id>NCT02581176</nct_id>
  </id_info>
  <brief_title>Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study</brief_title>
  <acronym>CAP</acronym>
  <official_title>Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Akershus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-arm, phase IV trial, of apixaban as treatment of venous thrombosis in&#xD;
      patients with cancer. The current standard treatment of venous thrombosis in cancer patients&#xD;
      is subcutaneous injections with low molecular weight heparin. During the last 5 years several&#xD;
      new direct acting oral anticoagulants have been tested out as treatment of venous thrombosis.&#xD;
      But very few cancer patients were included in the phase III clinical trials of the direct&#xD;
      acting oral anticoagulants. Thus, there is a lack of information on how cancer patients with&#xD;
      venous thrombosis will respond to treatment with direct acting oral anticoagulants. The&#xD;
      current study will investigate the direct acting oral anticoagulant apixaban in cancer&#xD;
      patients with venous thrombosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent objectively confirmed venous thrombosis or death related to venous thrombosis</measure>
    <time_frame>6 months after inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Major or clinically relevant non-major bleeding</measure>
    <time_frame>6 months after inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>6 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>24 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent objectively confirmed venous thrombosis or death related to venous thrombosis</measure>
    <time_frame>24 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major or clinically relevant non-major bleeding</measure>
    <time_frame>24 months after inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Neoplasms</condition>
  <condition>Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban 10 mg two times daily for 1 week, then apixaban 5mg two times daily for 6 months, then apixaban 2.5 mg two times daily for as long as the treating physician finds it necessary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <arm_group_label>Apixaban</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A diagnosis of cancer, other than basal-cell or squamous-cell carcinoma of the skin,&#xD;
             within six months before enrollment. Any treatment for cancer within the previous six&#xD;
             months, or recurrent or metastatic cancer.&#xD;
&#xD;
          -  Objectively verified venous thrombosis&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anticoagulant therapy prior to trial entry for &gt; 96 hours&#xD;
&#xD;
          -  Severe thrombocytopenia (platelets &lt;50·109/L)&#xD;
&#xD;
          -  Severe renal failure - creatinine clearance &lt;30 ml/min&#xD;
&#xD;
          -  The patients will be treated with catheter based thrombolysis for deep venous&#xD;
             thrombosis or systemic thrombolysis for severe pulmonary embolism&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Childbearing potential without proper contraceptive measures&#xD;
&#xD;
          -  Drug abuse or mental disease that may interfere with treatment and follow-up.&#xD;
&#xD;
          -  Severe malabsorption so that oral treatment are expected to have reduced effect&#xD;
&#xD;
          -  Mechanical heart valves&#xD;
&#xD;
          -  Known allergy to apixaban&#xD;
&#xD;
          -  Active bleeding or severe risk of bleeding so that the risk of bleeding is considered&#xD;
             a greater danger than the risk of not treating the venous thrombosis&#xD;
&#xD;
          -  Clinically significant liver disease (e.g., acute hepatitis, chronic active hepatitis,&#xD;
             or cirrhosis)&#xD;
&#xD;
          -  Concomitant use of strong cytochrome P-450 3A4 inhibitors (e.g., human&#xD;
             immunodeficiency virus protease inhibitors or systemic ketoconazole, voriconazole or&#xD;
             posaconazole) or inducers (e.g., rifampicin, carbamazepine, or phenytoin). Fluconazol&#xD;
             is allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders EA Dahm, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Akershus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vestre Viken- Drammen Hospital</name>
      <address>
        <city>Drammen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vestre Viken - Bærum sykehus</name>
      <address>
        <city>Gjettum</city>
        <zip>1346</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Østfold Hospital Kalnes</name>
      <address>
        <city>Sarpsborg</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volda Hospital</name>
      <address>
        <city>Volda</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>October 19, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <last_update_submitted>June 24, 2018</last_update_submitted>
  <last_update_submitted_qc>June 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Akershus</investigator_affiliation>
    <investigator_full_name>Anders Dahm</investigator_full_name>
    <investigator_title>Senior Consultant, Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

